Samantha Hollingworth

Dr. Samantha Hollingworth is an Honorary Senior Lecturer in the School of Pharmacy and Pharmaceutical Sciences at the University of Queensland, with expertise as an epidemiologist and health economist specializing in pharmacoepidemiology and health technology assessment. She earned her BSc (Hons) and Master of Public Health (MPH) from the University of Queensland and her PhD from Monash University. Her academic career includes extensive experience as a consultant evaluating submissions for medicine subsidies on Australia's Pharmaceutical Benefits Scheme. Hollingworth has lived and worked in Australia, Canada, Indonesia, the United Kingdom, and Ghana, contributing to international health projects in Indonesia and ongoing initiatives in health technology assessment and medicines use in Ghana and sub-Saharan Africa. She holds honorary or visiting appointments at the University of Queensland, Imperial College London through the International Decision Support Initiative, and Kwame Nkrumah University of Science and Technology in Kumasi, Ghana. Collaborating with networks of clinicians and health professionals, she investigates medicine utilization and adverse effects across general practice, cancer, psychiatry, neurology, and internal medicine, emphasizing data-driven evidence for decision-making and implementation science in low- and middle-income countries.

Hollingworth has coordinated courses, lectured, and tutored in undergraduate and postgraduate programs, serving as Foundation Coordinator for the University of Queensland's Master of Pharmaceutical Industry Practice since 2019 and advising diverse PhD and student research projects. Her influential publications include 'International trends in clozapine use: a study in 17 countries' (2017, Acta Psychiatrica Scandinavica), 'The impact of clozapine on hospital use: a systematic review and meta-analysis' (2017, Acta Psychiatrica Scandinavica), 'Marked increase in proton pump inhibitors use in Australia' (2010, Pharmacoepidemiology and Drug Safety), 'Affective and anxiety disorders: prevalence, treatment and antidepressant medication use' (2010, Australian & New Zealand Journal of Psychiatry), 'Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: a randomized controlled trial (CODEX)' (2018, Diabetes, Obesity and Metabolism), 'Measuring medicine use: applying ATC/DDD methodology to real-world data' (2021, Pharmacy), and numerous studies on opioid prescribing patterns, antidepressant use, antimicrobial stewardship, and health technology assessment capacity in sub-Saharan Africa. Her work advances understanding of medicine use trends, policy implications, and equitable health systems globally.

Professional Email: s.hollingworth@uq.edu.au